Driving operational excellence with SQDECC
SQDECC is an industry-recognized model that enables the operational teams to get a unified view of their efficiency across parameters of Safety, Quality, Delivery, Engagement, Cost, and Compliance (SQDECC).
Achieving Biologics manufacturing milestones using a systemic approach to Technology Transfer
Learn how Syngene achieves manufacturing milestones in Biologics using a systemic approach to 100% ‘first-time right’ technology transfer.
How Organocatalysis discovered by Nobel laureates revolutionised drug development and production in Syngene
David Macmillan and Benjamin List are joint Nobel prize winners for 2021 in chemistry for their ground-breaking work on the development of asymmetric organocatalysis. The efficacy of organocatalysis in asymmetric synthesis has influenced the field of organic synthesis since the early 2000s. Recognising this powerful science, the Discovery Chemistry team at Syngene has transitioned from […]
In silico toxicity prediction using Derek Nexus for predicting skin sensitization, phototoxicity, hepatotoxicity and in vitro hERG inhib
In silico toxicity evaluation using Derek® Nexus for quicker and cost-effective screening for skin sensitization phototoxicity, hepatotoxicity, and in vitro hERG channel inhibition
Chromatography based purification of retro virus spikes
Presenting the data for purification of Retro virus using ion exchange chromatography where the condition for purification was optimized.
Early discovery due diligence of immuno target through multi pronged approaches
Our approach to informed decision-making during early discovery stage to create novel, best-in-class drugs.
Effect of Container Closure Systems on Stability of Pharmaceutical Products
Case studies on how Syngene handled unique problems in Stability Testing arising from packaging material.
Efficient Scale Up of Therapeutic Antibody Manufacturing Processes
Syngene’s ‘first-time-right’ Technology Transfer approach to achieve timely clinical and commercial milestones.
Mechanistic insights into drug-drug interactions from large-scale toxicogenomics data
How to manage the risk of drug-drug interactions in drug development and during poly therapy especially with elderly patients.
Profiling CEACAM7 as a potential target for pancreatic cancer
Demonstrating the therapeutic edge of targeting CEACAM7 in pancreatic cancer using an integrative approach between biology and bioinformatics.